Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment.
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment.
复制标题
肿瘤微环境中免疫细胞对卵巢癌预后的调节。
DOI：
10.3390/cancers10090302
复制
发表时间：
2018-09-01
期刊：
影响因子：
5.2
通讯作者：
Stiff PJ
中科院分区：
文献类型：
--
作者：
Drakes ML;Stiff PJ
据估计，2018年美国将有22240例卵巢癌新病例和14070例因这种恶性肿瘤死亡。这种疾病最常见的亚组是高级别浆液性卵巢癌（HGSOC），它以其侵袭性、高复发率、转移到其他部位以及对常规治疗产生耐药性而闻名。从预先存在的免疫细胞功能的角度理解卵巢癌肿瘤微环境（TME）是很重要的，因为免疫活性细胞对于建立强大的抗肿瘤反应以防止可见的肿瘤病变、疾病进展或复发至关重要。由先天和适应性免疫细胞、代谢途径、细胞内信号分子和大量可溶性因子组成的网络塑造了TME的致病性质，是对常规治疗和免疫治疗反应以及随后生存率的有用预后指标。本文综述了卵巢癌TME中的关键免疫细胞和可溶性分子，这些细胞和可溶性分子在有效抗肿瘤免疫的发展中起重要作用，以及那些损害效应T细胞活性的细胞。更深入地了解HGSOC TME将揭示潜在的免疫生物标志物，以帮助早期发现这种疾病，以及可能有针对性地推进新疗法的设计，从而诱导有效的抗肿瘤免疫和生存益处。
It is estimated that in the United States in 2018 there will be 22,240 new cases of ovarian cancer and 14,070 deaths due to this malignancy. The most common subgroup of this disease is high-grade serous ovarian cancer (HGSOC), which is known for its aggressiveness, high recurrence rate, metastasis to other sites, and the development of resistance to conventional therapy. It is important to understand the ovarian cancer tumor microenvironment (TME) from the viewpoint of the function of pre-existing immune cells, as immunocompetent cells are crucial to mounting robust antitumor responses to prevent visible tumor lesions, disease progression, or recurrence. Networks consisting of innate and adaptive immune cells, metabolic pathways, intracellular signaling molecules, and a vast array of soluble factors, shape the pathogenic nature of the TME and are useful prognostic indicators of responses to conventional therapy and immunotherapy, and subsequent survival rates. This review highlights key immune cells and soluble molecules in the TME of ovarian cancer, which are important in the development of effective antitumor immunity, as well as those that impair effector T cell activity. A more insightful knowledge of the HGSOC TME will reveal potential immune biomarkers to aid in the early detection of this disease, as well as biomarkers that may be targeted to advance the design of novel therapies that induce potent antitumor immunity and survival benefit.
登录
查看更多内容
影响因子：
11.5
作者：
Bol, Kalijn F.;Schreibelt, Gerty;Figdor, Carl G.
通讯作者：
Figdor, Carl G.
PD-1和PD-L1检查点信号传导抑制癌症免疫疗法：机制，组合和临床结果。
影响因子：
5.6
作者：
Alsaab HO;Sau S;Alzhrani R;Tatiparti K;Bhise K;Kashaw SK;Iyer AK
通讯作者：
Iyer AK
影响因子：
4.4
作者：
Bouzin, Caroline;Brouet, Agnes;Feron, Olivier
通讯作者：
Feron, Olivier
影响因子：
--
作者：
Chen S;Zhang L;Yan G;Cheng S;Fathy AH;Yan N;Zhao Y
通讯作者：
Zhao Y
影响因子：
8.8
作者：
Aras S;Zaidi MR
通讯作者：
Zaidi MR